| Antitumor effects and drug interactions of the proteasome inhibitor bortezomib (PS341) in gastric cancer cells. | |
| | |
MedLine Citation:
|
PMID: 17762396 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
The proteasome inhibitor bortezomib (PS341) inhibits the function of the 26S proteasome and has been extensively investigated in the clinical setting of hematologic malignancies. Remarkable efficacy has been reported in the treatment of multiple myeloma, but there have been few studies of its use in the treatment of gastrointestinal malignancy, especially gastric cancer. Here, we demonstrate its efficacy, both alone and in combination with other cytotoxic agents, in gastric cancer cell lines. The human gastric cancer cell lines AZ521, MKN45 and NUGC3 were used as experimental models. Bortezomib produced significant growth inhibition in these cells (mean IC50 values: 1.26, 9.44 and 8.63 micromol/l, respectively) and was also observed to decrease the activity of the extracellular signal-regulated kinase 1/2 and Akt signal pathways, increasing the accumulation of p21. Cell-cycle analysis revealed that a low concentration of bortezomib (10-100 nmol/l) increased accumulation in the G1 phase. Moreover, bortezomib showed synergistic growth inhibition in combination with the conventional cytotoxic agents 5-fluorouracil, paclitaxel, doxorubicin and SN-38, and also downregulates the activity of nuclear factor -kappaB, which is induced by these agents. Our results demonstrate that bortezomib could be an effective antitumor agent in the treatment of gastric cancer, both as single-agent therapy and in combination with conventional chemotherapeutic agents. |
| | |
Authors:
|
Takeo Fujita; Hiroyoshi Doihara; Kazuhiro Washio; Hideo Ino; Masakazu Murakami; Minoru Naito; Nobuyoshi Shimizu |
Related Documents
:
|
3780036 - Pepsinogen a polymorphism in gastric mucosa and urine, with special reference to patien... 8416206 - Fundal atrophic gastritis as a risk factor for gastric cancer. 14571786 - Analysis of the prognostic factors for liver metastasis of gastric cancer after hepatic... 17610016 - Secular trends in the use, quality, and outcomes of gastrectomy for noncardia gastric c... 1430456 - Amyloid deposition in seminal vesicles mimicking tumor invasion from bladder cancer: mr... 11349986 - The association between intra-oral cancer and surrogate markers of smoking and alcohol ... |
Publication Detail:
|
Type: Journal Article |
Journal Detail:
|
Title: Anti-cancer drugs Volume: 18 ISSN: 0959-4973 ISO Abbreviation: Anticancer Drugs Publication Date: 2007 Jul |
Date Detail:
|
Created Date: 2007-08-31 Completed Date: 2007-09-27 Revised Date: 2009-11-19 |
Medline Journal Info:
|
Nlm Unique ID: 9100823 Medline TA: Anticancer Drugs Country: England |
Other Details:
|
Languages: eng Pagination: 677-86 Citation Subset: IM |
Affiliation:
|
Department of Cancer and Thoracic Surgery, Okayama University School of Medicine, Okayama, Japan. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Antineoplastic Agents
/
pharmacology* Boronic Acids / pharmacology* Cell Cycle / drug effects Cell Line, Tumor Cell Survival / drug effects Dose-Response Relationship, Drug Drug Synergism Extracellular Signal-Regulated MAP Kinases / biosynthesis Humans Protease Inhibitors / pharmacology* Proteasome Endopeptidase Complex / antagonists & inhibitors* Proto-Oncogene Proteins c-akt / biosynthesis Pyrazines / pharmacology* Stomach Neoplasms* / enzymology, pathology |
| Chemical | |
Reg. No./Substance:
|
0/Antineoplastic Agents; 0/Boronic Acids; 0/Protease Inhibitors; 0/Pyrazines; 0/bortezomib; EC 2.7.11.1/Proto-Oncogene Proteins c-akt; EC 2.7.11.24/Extracellular Signal-Regulated MAP Kinases; EC 3.4.25.1/Proteasome Endopeptidase Complex; EC 3.4.99.-/ATP dependent 26S protease |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Ukrain modulates glial fibrillary acidic protein, but not connexin 43 expression, and induces apopto...
Next Document: Weekly epirubicin and paclitaxel with granulocyte colony-stimulating factor support in previously un...